SEOM clinical guidelines in Hereditary Breast and ovarian cancer

• DOI: 10.1007/s12094-015-1435-3
• Publication Date: 2015-12-15T12:03:58Z
• Authors: G. Llort; I. Chirivella; R. Morales; R. Serrano; A. Beatriz Sanchez; A. Teulé; E. Lastra; J. Brunet; J. Balmaña; B. Graña
• Keywords: Penetrance; Prophylactic Mastectomy; BRCA Mutation; Oophorectomy

Approximately, 7 % of all breast cancers (BC) and 11–15 ovarian (OC) are associated with inherited predisposition, mainly related to germline mutations in high penetrance BRCA1/2 genes. Clinical criteria for genetic testing based on personal family history estimate a minimum 10 detection rate. Selection evolving according new advances this field the clinical utility testing. Multiplex panel carries its own challenges we recommend inclusion genes utility. We screening annual mammography from age 30 MRI 25 BRCA1 BRCA2 mutation carriers. Bilateral salpingo-oophorectomy should be offered women or mutation, between 35 40 years after completion childbearing, individualise earliest cancer diagnosed family. risk-reducing mastectomy is an option healthy carriers, as well contralateral young patients prior BC diagnosis. BRCA OC may influence their locoregional systemic treatment.